Furthermore, IKAROS regulates the expression of cell surface receptors, including CD34 and CD43, and these molecules give IKZF1-mutated Ph- B-ALL cells a leukemic growth advantage [110]. This evidence concerns the gene CD177 and acute lymphoblastic leukemia.